Pfizer's (PFE) Cibinqo Approved in EU for Treatment of Adults with Moderate-to-Severe Atopic Dermatitis

Low Valuations to Drive Pharma M&A in 2022 - Analyst

December 13, 2021 8:50 AM EST

In light of recently announced major biotech acquisitions - Dicerna (NASDAQ: DRNA) was acquired by Novo Nordisk (NYSE: NVO) for $38 (~80% premium) and Arena (NASDAQ: ARNA) now being acquired for $100/sh (~100% premium) by Pfizer... More

Pfizer (PFE) Raises Quarterly Dividend 2.6% to $0.40; 3% Yield

December 10, 2021 12:01 PM EST

Pfizer (NYSE: PFE) declared a quarterly dividend of $0.40 per share, or $1.6 annualized. This is a 2.6% increase from the prior dividend of $0.39.

The dividend will be payable on March 4, 2022, to stockholders of record on January 28, 2022, with an ex-dividend date of January 27,... More

Arvinas Inc. (ARVN) and Pfizer (PFE) Announce PROTAC Protein Degrader ARV-471 Continues to Demonstrate Encouraging Clinical Benefit Rate in Patients with Locally Advanced or Metastatic ER+/HER2- Breas

December 10, 2021 8:12 AM EST

Arvinas, Inc. (Nasdaq: ARVN) and Pfizer Inc. (NYSE: PFE) today announced an update on Phase 1 dose escalation data of ARV-471, a novel PROTAC® estrogen receptor (ER) degrader, which is being co-developed for the treatment of patients with locally advanced or metastatic ER-positive/human epidermal growth factor receptor 2 (HER2)-negative breast cancer (ER+/HER2-). These data were presented as a virtual spotlight poster session at the 2021 San Antonio Breast Cancer Symposium (SABCS) and showed:

ARV-471 demonstrated antitumor activity in CDK4/6 inhibitor-pretreated patients with a clinical benefit rate... More

Pfizer (PFE) PT Raised to $54 at Barclays

December 10, 2021 4:36 AM EST

Barclays analyst Carter Gould raised the price target on Pfizer (NYSE: PFE) to $54.00 (from $44.00) while maintaining a Equalweight rating.... More

CDC Expands Booster Recommendations To 16-and-17-year-olds - Bloomberg

December 9, 2021 2:30 PM EST

CDC Expands Booster Recommendations To 16-and-17-year-olds - Bloomberg

... More

Pfizer (PFE), BioNTech (BNTX) Confirm U.S. FDA Emergency Use Authorization of COVID-19 Vaccine Booster for Individuals 16 Years and Older

December 9, 2021 12:07 PM EST

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced that the U.S. Food and Drug Administration (FDA) has expanded the Emergency Use Authorization (EUA) of a booster dose of the Pfizer-BioNTech COVID-19 Vaccine to include individuals 16 years of age and older. The booster dose is to be administered at least six months after completion of the primary series and is the same formulation and dosage strength as the doses in the primary series.

Todays decision by the FDA to further expand the... More

U.S. makes 16- and 17-year-olds eligible for COVID-19 boosters

December 9, 2021 11:38 AM EST

By Michael Erman

(Reuters) -U.S. regulators on Thursday expanded eligibility for COVID-19 vaccine booster shots to 16- and 17-year-olds, as public health officials have urged Americans to get a third shot due to concerns about the new Omicron variant of the virus.

The U.S. Food and Drug Administration said it amended its emergency use authorization of Pfizer Inc and BioNTech SE's vaccine to allow youths aged 16-17 to receive a third shot at least six months after their second vaccine dose.

The U.S. Centers for Disease... More

FDA Expands Eligibility for Pfizer (PFE) -BioNTech (BNTX) COVID-19 Booster Dose to 16- and 17-Year-Olds

December 9, 2021 11:22 AM EST

Today, the U.S. Food and Drug Administration amended the emergency use authorization (EUA) for the Pfizer-BioNTech COVID-19 Vaccine, authorizing the use of a single booster dose for administration to individuals 16 and 17 years of age at least six months after completion of primary vaccination with the Pfizer-BioNTech COVID-19 Vaccine.

Vaccination and getting a booster when eligible, along with other preventive measures like masking and avoiding large crowds and poorly ventilated spaces, remain our most effective methods for fighting COVID-19, said Acting FDA Commissioner Janet Woodcock, M.D. As people gather indoors with family and friends for the holidays, we cant... More